The study objective is to see if IV Efgartigimod and Vyjuvek treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) and IV Efgartigimod treatment in Epidermolysis Bullosa Acquisita (EBA) improves wound healing and affects the levels of C7 antibody levels in serum. Fewer wounds, more rapidly healing wounds, and decreased C7 antibodies could improve quality of life.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Reduction in serum C7 antibody levels
Timeframe: 26 weeks
Adverse Events and Effects
Timeframe: 38 weeks
The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) improvement
Timeframe: 26 weeks